T

Takeda

Global biopharmaceutical firm; R&D-driven NMEs

Digital Health Intern

Summer 2026Updated
No salary listed
Internship
Bachelor's, Master's
Toronto, ON, Canada
HybridHybrid role requiring occasional travel within Ontario (<5%); primarily Toronto office with remote work.
Data & AnalyticsData Analysis

About the job

Requirements
  • Bachelor's degree in a related field.
  • Currently enrolled in the University of Toronto Master of Biotechnology program and part of the digital health stream.
  • Familiarity with and knowledge of digital health technologies and trends.
  • Proficiency in data analysis and visualization tools such as Microsoft Excel and Power BI.
  • Familiarity with agile development methodologies related to product development or project management.
  • Ability to communicate effectively with internal and external stakeholders through written reports and oral presentations.
  • Fluency in spoken and written English.
  • Ability to travel within Ontario to meetings or conferences less than 5% of the time.
Responsibilities
  • Support the Digital Health Lead in Canada with the development and implementation of patient-centric digital health solutions.
  • Adapt European and Canadian flagship infrastructure to specific needs in the Canadian patient journey.
  • Contribute to the digital health strategy by identifying and prioritizing digital leverage points and advancing the roadmap.
  • Leverage Artificial Intelligence powered analytics and automation tools to inform decision-making and optimize digital health solutions.
  • Support key cross-functional stakeholder management activities including workshops and project meetings.
  • Analyze internal and external data and materials to inform projects and assess opportunities.
  • Assist the Data, Digital and Technology team with efforts to facilitate adoption of new digital and Artificial Intelligence technologies.
  • Support change management and upskilling initiatives across the organization.
  • Conduct research on digital health trends and best practices.
  • Provide hands-on support with learning and experience sharing for the wider organization.
  • Participate actively in local and regional digital health communities.
  • Collaborate with cross-functional teams such as Data and Insights, Marketing, and Medical Affairs.
Desired Qualifications
  • Experience with Artificial Intelligence driven data analysis, automation platforms, and generative Artificial Intelligence tools.
  • Bilingual proficiency in French and English.

About the company

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval for MIMRYLO unlocks near-term U.S. oncology revenue.
  • Takeda expects ORZEYFUL U.S. launch by November 2026, pending DEA scheduling.
  • Q1 FY2026 new launches grew 22.6%, offsetting mature-brand declines and supporting guidance.

What critics are saying

  • May 18, 2026 AMITIZA verdict exposed Takeda to $2.6 billion treble-damage risk.
  • Takeda plans 4,500 FY2026 cuts, signaling launch execution pressure and organizational churn.
  • Patent erosion crushed VYVANSE sales 60.7% at constant currency in Q1 FY2026.

What makes Takeda unique

  • ORZEYFUL became the first orexin agonist approved for narcolepsy type 1 in 2026.
  • MIMRYLO offers first-in-class hepcidin mimetic therapy for polycythemia vera after FDA approval.
  • Takeda pairs global scale with Japanese discovery, including Shonan-led neurology innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Wellness Program
  • Tuition Reimbursement

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 30th, 2026
Takeda raises profit guidance to $7.7B as new launches offset 1% revenue decline

Takeda Pharmaceutical said first-half core revenue fell 1% at constant exchange rates to just over JPY 2.4 trillion, while core operating profit rose 0.7% to JPY 710.6 billion. The company raised full-year core operating profit guidance to JPY 1.19 trillion from JPY 1.16 trillion, mainly due to foreign-exchange assumptions. It kept its outlook for a low-single-digit revenue decline. Reported revenue rose 8.4% to JPY 2.407 trillion, helped by a weaker yen. New launches are central to growth. Narcolepsy drug ORZEYFUL launched in Japan and China and is expected in the US in early November; MIMRYLO is on sale in the US. Zasocitinib, a psoriasis drug, is under priority review in the US. Takeda also plans a Japan filing in fiscal 2027 for gastric cancer drug TAK-921, after a phase III trial met its survival endpoints.

Yahoo Finance
Oct 29th, 2026
Takeda first-half revenue rises 8.4% as it launches MIMRYLO and wins approvals for ORZEYFUL

Takeda reported first-half fiscal 2026 results on October 29, 2026, with revenue up 8.4% at actual exchange rates but down 1.0% at constant rates. Core operating profit rose 11.2%, and reported operating profit rose 60.4%, helped by the end of amortisation for VYVANSE assets and lower impairment charges. Core earnings per share were JPY 308, and adjusted free cash flow was JPY 325.7 billion. The company raised its full-year outlook, mainly because of currency gains. ORZEYFUL won approval in the US, Japan, and China for narcolepsy type 1. It launched in Japan and China on October 15; the US launch awaits Drug Enforcement Administration scheduling. MIMRYLO launched in the US in August for erythrocytosis in polycythemia vera. The US Food and Drug Administration accepted zasocitinib for Priority Review, and the European Medicines Agency is also reviewing it. Takeda will hold a Capital Markets Day in Tokyo on December 11, 2026.

Yahoo Finance
Oct 15th, 2026
Takeda launches first orexin agonist ORZEYFUL for narcolepsy type 1 in Japan and China

Takeda has launched ORZEYFUL (oveporexton) in Japan and China for narcolepsy type 1 (NT1), giving doctors first access to the drug. It is a first-in-class orexin receptor 2 agonist in tablet form, designed to treat the orexin deficiency behind the disease. China's National Medical Products Administration, the US Food and Drug Administration, and Japan's Ministry of Health, Labour and Welfare approved it within a month of each other. A US launch is set for next month, once Drug Enforcement Administration scheduling is complete. In Phase 3 studies, patients on ORZEYFUL showed significant improvements over placebo in wakefulness, sleepiness, cataplexy, and quality of life across 12 weeks. Common side effects include insomnia, urinary urgency, urinary frequency, and excessive saliva. Takeda says submissions to health authorities are underway worldwide.

Associated Press
Sep 9th, 2026
Trialbee unveils AI-powered patient screening chatbot at DPHARM 2026

Trialbee, a patient recruitment platform provider, will present at DPHARM 2026 in Boston on 15-16 September. The Swedish-American company will unveil AI-powered patient screening in its Honey Platform, enabling conversational AI chatbots to conduct initial candidate assessments whilst giving patients the option to speak with recruitment specialists. Trialbee will present jointly with pharmaceutical company Takeda on integrating their respective platforms to build research-ready patient communities that extend beyond single trials. The company will also participate in a panel discussing AI applications at clinical trial sites. The Honey Platform has added several AI features this year, including candidate summaries, duplicate detection, and recruitment data analysis. Trialbee supports over 6,000 research sites across 50 countries and reports a 91% repeat business rate with biopharmaceutical companies.

Associated Press
Sep 9th, 2026
Onco360 selected as specialty pharmacy partner for rare blood cancer drug MIMRYLO

Onco360, a US independent speciality pharmacy, has been selected by Takeda Pharmaceuticals as an ultra-narrow limited distribution partner for MIMRYLO (rusfertide). The treatment is indicated for erythrocytosis in adults with polycythemia vera. MIMRYLO is a mimetic of the endogenous hormone hepcidin that blocks the iron transporter ferroportin. This inhibition reduces iron availability for red blood cell production, resulting in lower hematocrit levels. The drug's approval was based on the phase 3 VERIFY study, a global, randomised, open-label clinical trial. The primary endpoint measured the proportion of patients achieving response during weeks 20-32, defined as the absence of phlebotomy eligibility. The most common adverse reactions were injection site reactions at 56% and anaemia at 16%.

INACTIVE